首页 > 最新文献

Open Respiratory Medicine Journal最新文献

英文 中文
Radial Endobronchial Ultrasound-guided Transbronchial Cryobiopsy versus Forceps Biopsy for the Diagnosis of Solitary Pulmonary Nodules: A Prospective Randomised Trial 桡骨支气管超声引导下经支气管低温活检与钳活检诊断孤立性肺结节:一项前瞻性随机试验
Q3 Medicine Pub Date : 2023-10-10 DOI: 10.2174/0118743064262132230922110818
Michael Brown, Phan Nguyen, Hubertus Jersmann, Mark Holmes, Michelle Wong
Background: Improvements in pulmonary diagnostic imaging and the development of lung cancer screening are increasing the prevalence of Solitary pulmonary nodules (SPNs). Fluoroscopically guided radial endobronchial ultrasound (EBUS) with transbronchial forceps biopsy (TB-FB) has been the conventional diagnostic method. Transbronchial cryobiopsy (TB-CB) is an alternative biopsy method. We sought to compare transbronchial cryobiopsy to transbronchial forceps biopsy for the diagnosis of SPNs. Methods: A prospective, single-centre, randomised controlled trial was conducted at the Royal Adelaide Hospital (RAH). Patients with SPNs were randomised to either 5 transbronchial forceps biopsies or one transbronchial cryobiopsy. Complete blinding of investigators and participants was not possible, as transbronchial cryobiopsy required general anaesthesia. The primary outcome was diagnostic yield with secondary outcomes of specimen size, diagnostic yield for subsets challenging to access with forceps and safety. Results: The overall diagnostic yield for the 28 enrolled subjects was 76.8%(22/28). The diagnostic yield was 91.7% (11/12 patients) for transbronchial cryobiopsy and 68.8% (11/16 patients) for forceps biopsy (p=0.14). Median biopsy sizes were consistently larger for the cryobiopsy arm at 7.0mm compared to 2.5mm(p<0.0001). An eccentric EBUS image signalling the probe was adjacent to the nodule occurred in 4/28 cases, and TB-CB confirmed a diagnosis in 3/3 randomised to this arm. There were no major complications with either technique. Conclusion: Transbronchial cryobiopsy under the guidance of fluoroscopy and radial EBUS facilitates larger biopsy specimens without a significant increase in major complications. Further research is required to confirm the effect on diagnostic yield; however, our study supports a role for TB-CB in the diagnosis of SPNs and small, nodule-adjacent biopsies. Clinical Trial Registration Number: Reference number of R20160213(HREC/16/RAH/37).
背景:肺部诊断影像学的改善和肺癌筛查的发展正在增加孤立性肺结节(SPNs)的患病率。透视引导下桡骨支气管超声(EBUS)与经支气管钳活检(TB-FB)一直是常规的诊断方法。经支气管低温活检(TB-CB)是另一种活检方法。我们试图比较经支气管冷冻活检和经支气管钳活检对SPNs的诊断。方法:在阿德莱德皇家医院(RAH)进行了一项前瞻性、单中心、随机对照试验。spn患者随机分为5次经支气管钳活检或1次经支气管冷冻活检。研究者和参与者不可能完全盲化,因为经支气管冷冻活检需要全身麻醉。主要结局是诊断的产出率,次要结局是标本的大小,难以使用镊子和安全的亚群的诊断的产出率。结果:28例入组患者的总诊断率为76.8%(22/28)。经支气管冷冻活检的诊断率为91.7%(11/12例),钳活检的诊断率为68.8%(11/16例)(p=0.14)。冷冻活检臂的中位活检尺寸始终大于2.5mm,为7.0mm (p<0.0001)。在4/28的病例中出现了偏心的EBUS图像,表明探针位于结节附近,该组随机分组的3/3的患者确诊为TB-CB。两种技术均无重大并发症。结论:在透视和桡骨EBUS指导下经支气管冷冻活检可使活检标本更大,且主要并发症明显增加。需要进一步的研究来确认对诊断率的影响;然而,我们的研究支持TB-CB在诊断spn和小结节邻近活检中的作用。临床试验注册号:参考号R20160213(HREC/16/RAH/37)。
{"title":"Radial Endobronchial Ultrasound-guided Transbronchial Cryobiopsy versus Forceps Biopsy for the Diagnosis of Solitary Pulmonary Nodules: A Prospective Randomised Trial","authors":"Michael Brown, Phan Nguyen, Hubertus Jersmann, Mark Holmes, Michelle Wong","doi":"10.2174/0118743064262132230922110818","DOIUrl":"https://doi.org/10.2174/0118743064262132230922110818","url":null,"abstract":"Background: Improvements in pulmonary diagnostic imaging and the development of lung cancer screening are increasing the prevalence of Solitary pulmonary nodules (SPNs). Fluoroscopically guided radial endobronchial ultrasound (EBUS) with transbronchial forceps biopsy (TB-FB) has been the conventional diagnostic method. Transbronchial cryobiopsy (TB-CB) is an alternative biopsy method. We sought to compare transbronchial cryobiopsy to transbronchial forceps biopsy for the diagnosis of SPNs. Methods: A prospective, single-centre, randomised controlled trial was conducted at the Royal Adelaide Hospital (RAH). Patients with SPNs were randomised to either 5 transbronchial forceps biopsies or one transbronchial cryobiopsy. Complete blinding of investigators and participants was not possible, as transbronchial cryobiopsy required general anaesthesia. The primary outcome was diagnostic yield with secondary outcomes of specimen size, diagnostic yield for subsets challenging to access with forceps and safety. Results: The overall diagnostic yield for the 28 enrolled subjects was 76.8%(22/28). The diagnostic yield was 91.7% (11/12 patients) for transbronchial cryobiopsy and 68.8% (11/16 patients) for forceps biopsy (p=0.14). Median biopsy sizes were consistently larger for the cryobiopsy arm at 7.0mm compared to 2.5mm(p<0.0001). An eccentric EBUS image signalling the probe was adjacent to the nodule occurred in 4/28 cases, and TB-CB confirmed a diagnosis in 3/3 randomised to this arm. There were no major complications with either technique. Conclusion: Transbronchial cryobiopsy under the guidance of fluoroscopy and radial EBUS facilitates larger biopsy specimens without a significant increase in major complications. Further research is required to confirm the effect on diagnostic yield; however, our study supports a role for TB-CB in the diagnosis of SPNs and small, nodule-adjacent biopsies. Clinical Trial Registration Number: Reference number of R20160213(HREC/16/RAH/37).","PeriodicalId":39127,"journal":{"name":"Open Respiratory Medicine Journal","volume":"16 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-10-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"136360533","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A Bioinformatic Algorithm based on Pulmonary Endoarterial Biopsy for Targeted Pulmonary Arterial Hypertension Therapy 基于肺动脉活检的生物信息学算法在肺动脉高压靶向治疗中的应用
Q3 Medicine Pub Date : 2023-10-04 DOI: 10.2174/18743064-v17-230927-2023-9
Abraham Rothman, David Mann, Jose A. Nunez, Reinhardt Tarmidi, Humberto Restrepo, Valeri Sarukhanov, Roy Williams, William N. Evans
Background: Optimal pharmacological therapy for pulmonary arterial hypertension (PAH) remains unclear, as pathophysiological heterogeneity may affect therapeutic outcomes. A ranking methodology based on pulmonary vascular genetic expression analysis could assist in medication selection and potentially lead to improved prognosis. Objective: To describe a bioinformatics approach for ranking currently approved pulmonary arterial antihypertensive agents based on gene expression data derived from percutaneous endoarterial biopsies in an animal model of pulmonary hypertension. Methods: We created a chronic PAH model in Micro Yucatan female swine by surgical anastomosis of the left pulmonary artery to the descending aorta. A baseline catheterization, angiography and pulmonary endoarterial biopsy were performed. We obtained pulmonary vascular biopsy samples by passing a biopsy catheter through a long 8 French sheath, introduced via the carotid artery, into 2- to 3-mm peripheral pulmonary arteries. Serial procedures were performed on days 7, 21, 60, and 180 after surgical anastomosis. RNA microarray studies were performed on the biopsy samples. Results: Utilizing the medical literature, we developed a list of PAH therapeutic agents, along with a tabulation of genes affected by these agents. The effect on gene expression from pharmacogenomic interactions was used to rank PAH medications at each time point. The ranking process allowed the identification of a theoretical optimum three-medication regimen. Conclusion: We describe a new potential paradigm in the therapy for PAH, which would include endoarterial biopsy, molecular analysis and tailored pharmacological therapy for patients with PAH.
背景:肺动脉高压(PAH)的最佳药物治疗尚不清楚,因为病理生理异质性可能影响治疗结果。基于肺血管基因表达分析的排序方法有助于药物选择,并有可能改善预后。目的:描述一种生物信息学方法,基于肺动脉高压动物模型经皮动脉内活检获得的基因表达数据,对目前批准的肺动脉降压药进行排名。方法:采用左肺动脉与降主动脉吻合的方法,建立微尤卡坦母猪慢性肺动脉高压模型。进行了基线导管穿刺、血管造影和肺动脉活检。我们通过将活检导管穿过长8法国鞘,经颈动脉插入2至3毫米的外周肺动脉,获得肺血管活检样本。术后第7天、21天、60天和180天进行了一系列手术。对活检样本进行RNA微阵列研究。结果:利用医学文献,我们开发了多环芳烃治疗剂的列表,以及受这些药物影响的基因表。药物基因组相互作用对基因表达的影响用于对每个时间点的多环芳烃药物进行排序。排序过程允许确定理论上最优的三种药物治疗方案。结论:我们描述了一种新的治疗PAH的潜在模式,包括动脉内活检、分子分析和针对PAH患者的量身定制的药物治疗。
{"title":"A Bioinformatic Algorithm based on Pulmonary Endoarterial Biopsy for Targeted Pulmonary Arterial Hypertension Therapy","authors":"Abraham Rothman, David Mann, Jose A. Nunez, Reinhardt Tarmidi, Humberto Restrepo, Valeri Sarukhanov, Roy Williams, William N. Evans","doi":"10.2174/18743064-v17-230927-2023-9","DOIUrl":"https://doi.org/10.2174/18743064-v17-230927-2023-9","url":null,"abstract":"Background: Optimal pharmacological therapy for pulmonary arterial hypertension (PAH) remains unclear, as pathophysiological heterogeneity may affect therapeutic outcomes. A ranking methodology based on pulmonary vascular genetic expression analysis could assist in medication selection and potentially lead to improved prognosis. Objective: To describe a bioinformatics approach for ranking currently approved pulmonary arterial antihypertensive agents based on gene expression data derived from percutaneous endoarterial biopsies in an animal model of pulmonary hypertension. Methods: We created a chronic PAH model in Micro Yucatan female swine by surgical anastomosis of the left pulmonary artery to the descending aorta. A baseline catheterization, angiography and pulmonary endoarterial biopsy were performed. We obtained pulmonary vascular biopsy samples by passing a biopsy catheter through a long 8 French sheath, introduced via the carotid artery, into 2- to 3-mm peripheral pulmonary arteries. Serial procedures were performed on days 7, 21, 60, and 180 after surgical anastomosis. RNA microarray studies were performed on the biopsy samples. Results: Utilizing the medical literature, we developed a list of PAH therapeutic agents, along with a tabulation of genes affected by these agents. The effect on gene expression from pharmacogenomic interactions was used to rank PAH medications at each time point. The ranking process allowed the identification of a theoretical optimum three-medication regimen. Conclusion: We describe a new potential paradigm in the therapy for PAH, which would include endoarterial biopsy, molecular analysis and tailored pharmacological therapy for patients with PAH.","PeriodicalId":39127,"journal":{"name":"Open Respiratory Medicine Journal","volume":"16 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-10-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135647605","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Usefulness of High-resolution Computed Tomography for Macrolide Therapy of Idiopathic Bronchiectasis. 高分辨率计算机断层扫描在大环内酯类药物治疗特发性支气管扩张症中的应用。
Q3 Medicine Pub Date : 2023-08-29 eCollection Date: 2023-01-01 DOI: 10.2174/18743064-v17-230822-2022-27
Zenya Saito, Masahiro Yoshida, Shota Uchiyama, Saiko Nishioka, Kentaro Tamura, Nobumasa Tamura

Background: High-resolution computed tomography (HRCT) correlates with clinical symptoms, respiratory function, and quality of life in bronchiectasis.

Objective: We aimed to investigate the relationship between macrolide and acute exacerbation (AE) in idiopathic bronchiectasis classified by the Bronchiectasis Radiologically Indexed CT Score (BRICS).

Methods: We retrospectively reviewed the medical records of patients diagnosed with idiopathic bronchiectasis between April 2014 and December 2020 at a single hospital. Overall, 115 patients with idiopathic bronchiectasis were selected and divided into three groups, according to the BRICS. Each group was divided into subgroups with and without macrolide therapy, and the number of patients with AE in each group was retrospectively compared.

Results: About 45, 48, and 22 patients were included in the mild, moderate, and severe groups, respectively. In the mild group, the subgroup with macrolide therapy had significantly fewer patients with single AE than those without macrolide ( P = 0.029). There was no significant difference in the moderate and severe groups ( P = 1.00 and 0.64, respectively). In the multiple AE, the subgroup with macrolide therapy had significantly fewer patients than those without macrolide therapy in the mild, moderate, and severe groups ( P = 0.024, 0.029, and 0.026, respectively).

Conclusion: HRCT severity assessment might be useful in predicting treatment efficacy in patients with idiopathic bronchiectasis without previous AEs. Further large-scale clinical trials are required on the usefulness of HRCT in the future.

背景:高分辨率计算机断层扫描(HRCT)与支气管扩张症的临床症状、呼吸功能和生活质量相关。目的:我们旨在研究大环内酯类药物与支气管扩张症急性加重期(AE)的关系。方法:回顾性回顾2014年4月至2020年12月在一家医院诊断为特发性支气管扩张症的患者的医疗记录。根据金砖国家,总共选择了115名特发性支气管扩张症患者,并将其分为三组。每组被分为接受和不接受大环内酯类药物治疗的亚组,并对每组AE患者的数量进行回顾性比较。结果:约45、48和22名患者分别被纳入轻度、中度和重度组。在轻度组中,接受大环内酯类药物治疗的亚组发生单一AE的患者明显少于未接受大环环内酯类治疗的患者(P=0.029)。中度组和重度组之间没有显著差异(分别为P=1.00和0.64)。在多发性AE中,在轻度、中度和重度组中,接受大环内酯类药物治疗的亚组患者明显少于未接受大环利类药物治疗组(分别为P=0.024、0.029和0.026)。结论:HRCT严重程度评估可能有助于预测无既往AE的特发性支气管扩张患者的治疗效果。未来还需要对HRCT的有用性进行进一步的大规模临床试验。
{"title":"Usefulness of High-resolution Computed Tomography for Macrolide Therapy of Idiopathic Bronchiectasis.","authors":"Zenya Saito,&nbsp;Masahiro Yoshida,&nbsp;Shota Uchiyama,&nbsp;Saiko Nishioka,&nbsp;Kentaro Tamura,&nbsp;Nobumasa Tamura","doi":"10.2174/18743064-v17-230822-2022-27","DOIUrl":"https://doi.org/10.2174/18743064-v17-230822-2022-27","url":null,"abstract":"<p><strong>Background: </strong>High-resolution computed tomography (HRCT) correlates with clinical symptoms, respiratory function, and quality of life in bronchiectasis.</p><p><strong>Objective: </strong>We aimed to investigate the relationship between macrolide and acute exacerbation (AE) in idiopathic bronchiectasis classified by the Bronchiectasis Radiologically Indexed CT Score (BRICS).</p><p><strong>Methods: </strong>We retrospectively reviewed the medical records of patients diagnosed with idiopathic bronchiectasis between April 2014 and December 2020 at a single hospital. Overall, 115 patients with idiopathic bronchiectasis were selected and divided into three groups, according to the BRICS. Each group was divided into subgroups with and without macrolide therapy, and the number of patients with AE in each group was retrospectively compared.</p><p><strong>Results: </strong>About 45, 48, and 22 patients were included in the mild, moderate, and severe groups, respectively. In the mild group, the subgroup with macrolide therapy had significantly fewer patients with single AE than those without macrolide ( <i>P</i> = 0.029). There was no significant difference in the moderate and severe groups ( <i>P</i> = 1.00 and 0.64, respectively). In the multiple AE, the subgroup with macrolide therapy had significantly fewer patients than those without macrolide therapy in the mild, moderate, and severe groups ( <i>P</i> = 0.024, 0.029, and 0.026, respectively).</p><p><strong>Conclusion: </strong>HRCT severity assessment might be useful in predicting treatment efficacy in patients with idiopathic bronchiectasis without previous AEs. Further large-scale clinical trials are required on the usefulness of HRCT in the future.</p>","PeriodicalId":39127,"journal":{"name":"Open Respiratory Medicine Journal","volume":"17 ","pages":"e187430642307250"},"PeriodicalIF":0.0,"publicationDate":"2023-08-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10507212/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"71427651","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Diagnosis and Management of Patients with Connective Tissue Disease-related Fibrosing Interstitial Lung Diseases. 结缔组织疾病相关纤维化间质性肺疾病患者的诊断和治疗。
Q3 Medicine Pub Date : 2023-08-15 eCollection Date: 2023-01-01 DOI: 10.2174/18743064-v17-e230714-2022-26
Bonnie Wang, Vivek Nagaraja

Background: Fibrotic interstitial lung disease is an important driver of morbidity and mortality in patients with connective tissue diseases (CTD). Due to the lack of prospective randomized trial data in this population, practice pattern variation exists in the management of patients with CTD.

Case presentation: This case series describes three patients, each with a different background of autoimmunity complicated by fibrotic interstitial lung disease (ILD). We review their initial presentations, follow their disease trajectories on currently available treatments, and reference forthcoming clinical trials.

Conclusion: Clinical impact or potential implications. Response to immunosuppression and antifibrotic therapy is variable in patients with connective tissue disease-related fibrosing interstitial lung disease. Data from prospective clinical trials and longitudinal registry studies will conceivably provide additional insight into improving care for these patients.

背景:纤维间质性肺病是结缔组织疾病(CTD)患者发病率和死亡率的重要驱动因素。由于缺乏该人群的前瞻性随机试验数据,CTD患者的管理存在实践模式差异。病例介绍:本病例系列描述了三名患者,每个患者都有不同的自身免疫背景,并伴有纤维间质性肺病(ILD)。我们回顾了他们的初步陈述,跟踪了他们目前可用治疗方法的疾病轨迹,并参考了即将进行的临床试验。结论:临床影响或潜在影响。结缔组织疾病相关纤维化间质性肺病患者对免疫抑制和抗纤维化治疗的反应是可变的。来自前瞻性临床试验和纵向注册研究的数据将为改善这些患者的护理提供更多的见解。
{"title":"Diagnosis and Management of Patients with Connective Tissue Disease-related Fibrosing Interstitial Lung Diseases.","authors":"Bonnie Wang,&nbsp;Vivek Nagaraja","doi":"10.2174/18743064-v17-e230714-2022-26","DOIUrl":"https://doi.org/10.2174/18743064-v17-e230714-2022-26","url":null,"abstract":"<p><strong>Background: </strong>Fibrotic interstitial lung disease is an important driver of morbidity and mortality in patients with connective tissue diseases (CTD). Due to the lack of prospective randomized trial data in this population, practice pattern variation exists in the management of patients with CTD.</p><p><strong>Case presentation: </strong>This case series describes three patients, each with a different background of autoimmunity complicated by fibrotic interstitial lung disease (ILD). We review their initial presentations, follow their disease trajectories on currently available treatments, and reference forthcoming clinical trials.</p><p><strong>Conclusion: </strong>Clinical impact or potential implications. Response to immunosuppression and antifibrotic therapy is variable in patients with connective tissue disease-related fibrosing interstitial lung disease. Data from prospective clinical trials and longitudinal registry studies will conceivably provide additional insight into improving care for these patients.</p>","PeriodicalId":39127,"journal":{"name":"Open Respiratory Medicine Journal","volume":"17 ","pages":"e187430642306150"},"PeriodicalIF":0.0,"publicationDate":"2023-08-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10507213/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"71427649","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Role of Flexible Bronchoscopy using Biopsy Forceps as the Initial Attempt for Headscarf Pin Aspiration Extraction. 使用活检钳进行柔性支气管镜检查作为头巾针抽吸的初步尝试
Q3 Medicine Pub Date : 2023-08-07 eCollection Date: 2023-01-01 DOI: 10.2174/18743064-v17-e230718-2023-5
Mia Elhidsi, Dicky Soehardiman, Wahju Aniwidyaningsih, Mochamad Fahmi Alatas, Ginanjar Arum Desianti, Prasenohadi Pradono

Introduction: Flexible bronchoscopy is a less invasive procedure for extracting foreign bodies from the airways. However, studies on the extraction of headscarf pins are still very limited to determine the efficacy and safety of headscarf pin extraction using flexible bronchoscopy with biopsy forceps.

Methods: This retrospective study was conducted at Persahabatan Hospital, Jakarta, Indonesia, on patients who had been treated in this hospital for headscarf pin extraction between January 2013 and February 2023. Fibreoptic bronchoscopy was performed under general anaesthesia. The pin was removed using Radial Jaw 4 mm single-use pulmonary biopsy forceps. The impacted sharp tip of the pin was freed first, and the proximal part of the pin body was gripped using biopsy forceps. Once a firm hold of the sharp end or the proximal part of the pin was secured, the bronchoscope and forceps were both slowly withdrawn under direct vision.

Results: Thirty-two cases with headscarf pin aspiration were managed by fibreoptic bronchoscopy. A total of 12 patients (37.5%) came without any respiratory complaints; however, an equal number complained of cough and 6 cases (18.7%) of haemoptysis. All the cases in which the pins were visible in the airway were found with the round head down and the sharp tip oriented superiorly in the airway and impacted in the mucosa. Fibreoptic bronchoscopy extraction succeeded in 31 cases (96.8%). Only one case was converted to surgery. There were no major complications.

Conclusion: Fibreoptic bronchoscopy with biopsy forceps under general anaesthesia is safe and effective for the removal of headscarf pin aspiration.

柔性支气管镜检查是一种从气道中取出异物的微创手术。然而,关于提取头针的研究仍然非常有限,无法确定使用带活检钳的柔性支气管镜进行头针提取的有效性和安全性。这项回顾性研究在印度尼西亚雅加达Persahabatan医院进行,对象是2013年1月至2023年2月期间在该医院接受头巾拔针治疗的患者。纤维支气管镜检查是在全身麻醉下进行的。使用径向钳口4mm一次性肺部活检钳取出针。首先释放受冲击的针头尖端,并使用活检钳夹住针头主体的近端。一旦牢牢抓住针头的尖端或近端,支气管镜和镊子都会在直视下慢慢取出。采用纤维支气管镜检查对32例头针抽吸患者进行了治疗。共有12名患者(37.5%)没有任何呼吸道疾病;然而,同样数量的患者抱怨咳嗽和6例(18.7%)咯血。所有在气道中可见钉的病例都是圆形头部朝下,尖锐尖端在气道中向上,并撞击在粘膜中。纤维支气管镜取出成功31例(96.8%),只有1例转为手术。没有出现重大并发症。在全身麻醉下用活检钳进行纤维支气管镜检查是安全有效的去除头针抽吸的方法。
{"title":"Role of Flexible Bronchoscopy using Biopsy Forceps as the Initial Attempt for Headscarf Pin Aspiration Extraction.","authors":"Mia Elhidsi,&nbsp;Dicky Soehardiman,&nbsp;Wahju Aniwidyaningsih,&nbsp;Mochamad Fahmi Alatas,&nbsp;Ginanjar Arum Desianti,&nbsp;Prasenohadi Pradono","doi":"10.2174/18743064-v17-e230718-2023-5","DOIUrl":"10.2174/18743064-v17-e230718-2023-5","url":null,"abstract":"<p><strong>Introduction: </strong>Flexible bronchoscopy is a less invasive procedure for extracting foreign bodies from the airways. However, studies on the extraction of headscarf pins are still very limited to determine the efficacy and safety of headscarf pin extraction using flexible bronchoscopy with biopsy forceps.</p><p><strong>Methods: </strong>This retrospective study was conducted at Persahabatan Hospital, Jakarta, Indonesia, on patients who had been treated in this hospital for headscarf pin extraction between January 2013 and February 2023. Fibreoptic bronchoscopy was performed under general anaesthesia. The pin was removed using Radial Jaw 4 mm single-use pulmonary biopsy forceps. The impacted sharp tip of the pin was freed first, and the proximal part of the pin body was gripped using biopsy forceps. Once a firm hold of the sharp end or the proximal part of the pin was secured, the bronchoscope and forceps were both slowly withdrawn under direct vision.</p><p><strong>Results: </strong>Thirty-two cases with headscarf pin aspiration were managed by fibreoptic bronchoscopy. A total of 12 patients (37.5%) came without any respiratory complaints; however, an equal number complained of cough and 6 cases (18.7%) of haemoptysis. All the cases in which the pins were visible in the airway were found with the round head down and the sharp tip oriented superiorly in the airway and impacted in the mucosa. Fibreoptic bronchoscopy extraction succeeded in 31 cases (96.8%). Only one case was converted to surgery. There were no major complications.</p><p><strong>Conclusion: </strong>Fibreoptic bronchoscopy with biopsy forceps under general anaesthesia is safe and effective for the removal of headscarf pin aspiration.</p>","PeriodicalId":39127,"journal":{"name":"Open Respiratory Medicine Journal","volume":" ","pages":"e187430642306220"},"PeriodicalIF":0.0,"publicationDate":"2023-08-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10487336/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"49262365","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Sex-specificity in Surgical Stages of Lung Cancer in Young Adults. 年轻人肺癌手术分期的性别特异性。
Q3 Medicine Pub Date : 2023-07-17 eCollection Date: 2023-01-01 DOI: 10.2174/18743064-v17-230818-2022-20
Mahdi Abdennadher, Mariem Hadj Dahmane, Sarra Zair, Hazem Zribi, Amina Abdelkbir, Imen Bouassida, Mouna Mlika, Imen Sahnoun, Amani Ben Mansour, Adel Marghli

Background: Young Patients with lung cancer represent a distinct subset of patients with this neoplasm. Young International studies show increased lung cancer rates in females, while the incidence in males continues to decline. There is evidence to suggest that this trend recurs in younger patients. We studied the effects of gender differences on the incidence of surgical stages of lung cancer in young adults and its mortality rate.

Methods: This study is a retrospective review (2010-2020) of young adults (aged under 45 years) with surgical-stage of lung cancer. We calculated female-to-male differences in incidence rate ratios, tumor characteristics, surgical management, and survival. Cumulative survival curves were generated by the Kaplan-Meier method.

Results: We examined 46 men and 24 women, under 45 years. Female patients were diagnosed at earlier stages. The proportion of stage IA disease was significantly higher in women than in men (46% versus 13%, respectively) (p=0.03). Women were more likely never smokers (42% versus 83%, p=0.02). A histologic subtype, females were more likely to have typical carcinoid tumors (13.54% versus 10.21% for males) (p>0.05). The largest histological type in men was adenocarcinoma (25.53% versus 4.16%, p>0.05). All the patients were operated. Three men had neoadjuvant chemotherapy and one was operated on for cerebral oligometastatic before his chest surgery. Adjuvant chemotherapy was given to 7 women and 21 men. Despite the small number of postoperative complications in our study (n= 8, 11.2%), the male sex was significant in predicting this complication (p<0.05). The mortality rate was 1.4%. The 5-year overall survival rates were 84% in men and 87% in women.

Conclusion: Our study identified sex differences in the incidence and mortality rates for surgical lung cancers in young adults, but the biological and endocrine mechanisms implicated in these disparities have not yet been determined.

背景:年轻肺癌患者是该肿瘤患者中的一个独特群体。国际青年研究显示,女性肺癌发病率上升,而男性发病率持续下降。有证据表明,这一趋势在年轻患者中再次出现。我们研究了性别差异对青壮年肺癌手术期发病率及其死亡率的影响:本研究是一项回顾性研究(2010-2020 年),研究对象为患有肺癌手术期的年轻成人(45 岁以下)。我们计算了女性与男性在发病率比、肿瘤特征、手术治疗和生存率方面的差异。采用卡普兰-梅耶法生成累积生存曲线:我们对 45 岁以下的 46 名男性和 24 名女性进行了研究。女性患者的确诊时间较早。女性ⅠA期患者的比例明显高于男性(分别为46%和13%)(P=0.03)。女性更有可能从不吸烟(42% 对 83%,P=0.02)。从组织学亚型来看,女性更有可能患有典型类癌(13.54% 对 10.21%)(P>0.05)。男性最大的组织学类型是腺癌(25.53%对4.16%,P>0.05)。所有患者都接受了手术。三名患者接受了新辅助化疗,一名患者在胸部手术前接受了脑寡转移手术。7名女性和21名男性接受了辅助化疗。尽管在我们的研究中术后并发症的发生率较低(8 例,11.2%),但男性在预测这种并发症方面具有重要意义(p 结论:我们的研究发现了青壮年手术肺癌发病率和死亡率的性别差异,但造成这些差异的生物和内分泌机制尚未确定。
{"title":"Sex-specificity in Surgical Stages of Lung Cancer in Young Adults.","authors":"Mahdi Abdennadher, Mariem Hadj Dahmane, Sarra Zair, Hazem Zribi, Amina Abdelkbir, Imen Bouassida, Mouna Mlika, Imen Sahnoun, Amani Ben Mansour, Adel Marghli","doi":"10.2174/18743064-v17-230818-2022-20","DOIUrl":"https://doi.org/10.2174/18743064-v17-230818-2022-20","url":null,"abstract":"<p><strong>Background: </strong>Young Patients with lung cancer represent a distinct subset of patients with this neoplasm. Young International studies show increased lung cancer rates in females, while the incidence in males continues to decline. There is evidence to suggest that this trend recurs in younger patients. We studied the effects of gender differences on the incidence of surgical stages of lung cancer in young adults and its mortality rate.</p><p><strong>Methods: </strong>This study is a retrospective review (2010-2020) of young adults (aged under 45 years) with surgical-stage of lung cancer. We calculated female-to-male differences in incidence rate ratios, tumor characteristics, surgical management, and survival. Cumulative survival curves were generated by the Kaplan-Meier method.</p><p><strong>Results: </strong>We examined 46 men and 24 women, under 45 years. Female patients were diagnosed at earlier stages. The proportion of stage IA disease was significantly higher in women than in men (46% <i>versus</i> 13%, respectively) (p=0.03). Women were more likely never smokers (42% <i>versus</i> 83%, p=0.02). A histologic subtype, females were more likely to have typical carcinoid tumors (13.54% <i>versus</i> 10.21% for males) (p>0.05). The largest histological type in men was adenocarcinoma (25.53% <i>versus</i> 4.16%, p>0.05). All the patients were operated. Three men had neoadjuvant chemotherapy and one was operated on for cerebral oligometastatic before his chest surgery. Adjuvant chemotherapy was given to 7 women and 21 men. Despite the small number of postoperative complications in our study (n= 8, 11.2%), the male sex was significant in predicting this complication (p<0.05). The mortality rate was 1.4%. The 5-year overall survival rates were 84% in men and 87% in women.</p><p><strong>Conclusion: </strong>Our study identified sex differences in the incidence and mortality rates for surgical lung cancers in young adults, but the biological and endocrine mechanisms implicated in these disparities have not yet been determined.</p>","PeriodicalId":39127,"journal":{"name":"Open Respiratory Medicine Journal","volume":"17 ","pages":"e187430642307140"},"PeriodicalIF":0.0,"publicationDate":"2023-07-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11041390/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140858811","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Average Volume-assured Pressure Support as Rescue Therapy after CPAP Failure in Pediatric Obstructive Sleep Apnea: A Retrospective Case Series Study. 平均容量保证压力支持作为儿童阻塞性睡眠呼吸暂停患者CPAP失败后的抢救治疗:回顾性病例系列研究
Q3 Medicine Pub Date : 2023-05-15 eCollection Date: 2023-01-01 DOI: 10.2174/18743064-v17-e230418-2022-18
Victor T Peng, Nauras Hwig, Anayansi Lasso-Pirot, Amal Isaiah, Montserrat Diaz-Abad

Background: Continuous positive airway pressure (CPAP) is frequently prescribed for patients with residual obstructive sleep apnea (OSA) following adenotonsillectomy.

Objectives: The goal was to examine the efficacy of noninvasive ventilation with average volume-assured pressure support (AVAPS) as a potential option for children with failed CPAP titration.

Methods: In a single-center retrospective study, we included children aged 1-17 years, with polysomnographically confirmed OSA who underwent AVAPS titration following failed CPAP titration. In addition to describing the clinical characteristics of the included patients, we compared polysomnographic parameters before and after AVAPS.

Results: Nine patients met the inclusion criteria; out of them, 8 (89%) were males with an age range of 6.7 ± 3.9 years and a body mass index percentile of 81.0 ± 28.9. Reasons for failed CPAP titration were: 3 (33%) patients due to inability to control apnea-hypopnea index (AHI), 3 (33%) patients due to sleep-related hypoventilation, 2 (22%) patients due to treatment-emergent central sleep apnea, and 1 (11%) patient due to intolerance to CPAP. AVAPS resulted in a greater reduction in AHI than CPAP (reduction following CPAP = 24.6 ± 29.3, reduction following AVAPS = 42.5 ± 37.6, p = 0.008). All patients had resolution of the problems which caused CPAP failure.

Conclusion: In this case a series of children with OSA and with failed CPAP titration, AVAPS resulted in a greater reduction in AHI compared with CPAP as well as resolution of the problems which caused CPAP failure.

持续气道正压通气(CPAP)常用于腺扁桃体切除术后残余阻塞性睡眠呼吸暂停(OSA)患者。目的是检查无创通气与平均容量保证压力支持(AVAPS)作为CPAP滴定失败儿童的潜在选择的有效性。在一项单中心回顾性研究中,我们纳入了1-17岁的儿童,多导睡眠图证实OSA,在CPAP滴定失败后接受AVAPS滴定。除了描述纳入患者的临床特征外,我们还比较了AVAPS前后的多导睡眠图参数。9例患者符合纳入标准;其中男性8例(89%),年龄6.7±3.9岁,体重指数为81.0±28.9。CPAP滴定失败的原因有:3例(33%)患者由于无法控制呼吸暂停低通气指数(AHI), 3例(33%)患者由于睡眠相关性低通气,2例(22%)患者由于治疗后出现的中枢性睡眠呼吸暂停,1例(11%)患者由于CPAP不耐受。AVAPS的AHI降低幅度大于CPAP (CPAP后降低= 24.6±29.3,AVAPS后降低= 42.5±37.6,p = 0.008)。所有患者均解决了导致CPAP失败的问题。在本病例中,一系列患有OSA且CPAP滴定失败的儿童,与CPAP相比,AVAPS导致AHI更大的降低,并解决了导致CPAP失败的问题。
{"title":"Average Volume-assured Pressure Support as Rescue Therapy after CPAP Failure in Pediatric Obstructive Sleep Apnea: A Retrospective Case Series Study.","authors":"Victor T Peng,&nbsp;Nauras Hwig,&nbsp;Anayansi Lasso-Pirot,&nbsp;Amal Isaiah,&nbsp;Montserrat Diaz-Abad","doi":"10.2174/18743064-v17-e230418-2022-18","DOIUrl":"10.2174/18743064-v17-e230418-2022-18","url":null,"abstract":"<p><strong>Background: </strong>Continuous positive airway pressure (CPAP) is frequently prescribed for patients with residual obstructive sleep apnea (OSA) following adenotonsillectomy.</p><p><strong>Objectives: </strong>The goal was to examine the efficacy of noninvasive ventilation with average volume-assured pressure support (AVAPS) as a potential option for children with failed CPAP titration.</p><p><strong>Methods: </strong>In a single-center retrospective study, we included children aged 1-17 years, with polysomnographically confirmed OSA who underwent AVAPS titration following failed CPAP titration. In addition to describing the clinical characteristics of the included patients, we compared polysomnographic parameters before and after AVAPS.</p><p><strong>Results: </strong>Nine patients met the inclusion criteria; out of them, 8 (89%) were males with an age range of 6.7 ± 3.9 years and a body mass index percentile of 81.0 ± 28.9. Reasons for failed CPAP titration were: 3 (33%) patients due to inability to control apnea-hypopnea index (AHI), 3 (33%) patients due to sleep-related hypoventilation, 2 (22%) patients due to treatment-emergent central sleep apnea, and 1 (11%) patient due to intolerance to CPAP. AVAPS resulted in a greater reduction in AHI than CPAP (reduction following CPAP = 24.6 ± 29.3, reduction following AVAPS = 42.5 ± 37.6, p = 0.008). All patients had resolution of the problems which caused CPAP failure.</p><p><strong>Conclusion: </strong>In this case a series of children with OSA and with failed CPAP titration, AVAPS resulted in a greater reduction in AHI compared with CPAP as well as resolution of the problems which caused CPAP failure.</p>","PeriodicalId":39127,"journal":{"name":"Open Respiratory Medicine Journal","volume":" ","pages":"e187430642303080"},"PeriodicalIF":0.0,"publicationDate":"2023-05-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10351336/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"46296120","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
CAR Selectively Enhances the Pulmonary Vasodilatory Effect of Fasudil in a Microsphere Model of Pulmonary Hypertension. CAR选择性地增强法舒地尔在肺动脉高压微球模型中的肺血管扩张作用
Q3 Medicine Pub Date : 2023-04-27 eCollection Date: 2023-01-01 DOI: 10.2174/18743064-v17-e230404-2022-19
Abraham Rothman, Humberto Restrepo, William N Evans, Valeri Sarukhanov, David Mann

Background: Despite the approval of several medications for pulmonary hypertension, morbidity and mortality are unacceptably high. Systemic hypotension may limit the use of pulmonary hypertension medications.

Objectives: This study aimed to assess whether the homing peptide CAR (CARSKNKDC) improves the vasodilatory selectivity of fasudil in the pulmonary circulation or systemic circulation in a porcine pulmonary hypertension model.

Materials and methods: Pulmonary hypertension (to approximately 2/3-3/4 systemic pressure levels) was induced by chronic and acute administration of microspheres in 3 micro Yucatan pigs (mean weight 19.9 kg, mean age 4.3 months). Fasudil (0.3 mg/kg) was administered without and with CAR (1.5 mg/kg), and the effect on aortic (Ao) and right ventricular (RV) pressure was recorded with indwelling catheters.

Results: Immediately after fasudil administration, there was a decrease in Ao pressure followed by prompt recovery to baseline. The RV pressure decrease was progressive and sustained. Fasudil alone resulted in a 12% decrease in RV pressure, whereas co-administration of CAR with fasudil resulted in a 22% decrease in RV pressure (p < 0.0001). Fasudil alone caused an average decrease of 34% in the RV/Ao pressure ratio, and fasudil + CAR caused an average decrease of 40% in the RV/Ao pressure ratio (p < 0.0001).

Conclusion: The homing peptide CAR selectively enhanced the acute vasodilatory effects of fasudil on the pulmonary vascular bed in a porcine experimental model of pulmonary hypertension.

尽管已经批准了几种治疗肺动脉高压的药物,但发病率和死亡率高得令人无法接受。系统性低血压可能限制肺动脉高压药物的使用。本研究旨在评估归巢肽CAR(CARSKNKDC)是否能改善猪肺动脉高压模型中法舒地尔在肺循环或体循环中的血管舒张选择性。在3头尤卡坦微型猪(平均体重19.9kg,平均年龄4.3个月)中,通过慢性和急性给药微球诱导肺动脉高压(达到约2/3-3/4的全身压力水平)。Fasudil(0.3 mg/kg)在无CAR和有CAR的情况下给药(1.5 mg/kg),并用留置导管记录对主动脉(Ao)和右心室(RV)压力的影响。法舒地尔给药后,Ao压力立即下降,随后迅速恢复到基线。RV压力的下降是渐进和持续的。Fasudil单独用药可使RV压力降低12%,而CAR与Fasudil联合用药可使右心室压力降低22%(p<0.0001)。Fasudil单药可使RV/Ao压力比平均降低34%,在猪肺动脉高压实验模型中,归巢肽CAR选择性增强了法舒地尔对肺血管床的急性血管舒张作用。
{"title":"CAR Selectively Enhances the Pulmonary Vasodilatory Effect of Fasudil in a Microsphere Model of Pulmonary Hypertension.","authors":"Abraham Rothman,&nbsp;Humberto Restrepo,&nbsp;William N Evans,&nbsp;Valeri Sarukhanov,&nbsp;David Mann","doi":"10.2174/18743064-v17-e230404-2022-19","DOIUrl":"10.2174/18743064-v17-e230404-2022-19","url":null,"abstract":"<p><strong>Background: </strong>Despite the approval of several medications for pulmonary hypertension, morbidity and mortality are unacceptably high. Systemic hypotension may limit the use of pulmonary hypertension medications.</p><p><strong>Objectives: </strong>This study aimed to assess whether the homing peptide CAR (CARSKNKDC) improves the vasodilatory selectivity of fasudil in the pulmonary circulation or systemic circulation in a porcine pulmonary hypertension model.</p><p><strong>Materials and methods: </strong>Pulmonary hypertension (to approximately 2/3-3/4 systemic pressure levels) was induced by chronic and acute administration of microspheres in 3 micro Yucatan pigs (mean weight 19.9 kg, mean age 4.3 months). Fasudil (0.3 mg/kg) was administered without and with CAR (1.5 mg/kg), and the effect on aortic (Ao) and right ventricular (RV) pressure was recorded with indwelling catheters.</p><p><strong>Results: </strong>Immediately after fasudil administration, there was a decrease in Ao pressure followed by prompt recovery to baseline. The RV pressure decrease was progressive and sustained. Fasudil alone resulted in a 12% decrease in RV pressure, whereas co-administration of CAR with fasudil resulted in a 22% decrease in RV pressure (p < 0.0001). Fasudil alone caused an average decrease of 34% in the RV/Ao pressure ratio, and fasudil + CAR caused an average decrease of 40% in the RV/Ao pressure ratio (p < 0.0001).</p><p><strong>Conclusion: </strong>The homing peptide CAR selectively enhanced the acute vasodilatory effects of fasudil on the pulmonary vascular bed in a porcine experimental model of pulmonary hypertension.</p>","PeriodicalId":39127,"journal":{"name":"Open Respiratory Medicine Journal","volume":"1 1","pages":"e187430642303160"},"PeriodicalIF":0.0,"publicationDate":"2023-04-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10351346/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"43728072","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Risk Factors Related to the Death of Admitted COVID-19 Patients: A Buffalo Study. 与新冠肺炎住院患者死亡相关的危险因素:水牛城研究。
Q3 Medicine Pub Date : 2023-04-06 eCollection Date: 2023-01-01 DOI: 10.2174/18743064-v17-e230322-2022-21
Doan Le Minh Hanh, Phan Thai Hao, Do Thi Tuong Oanh, Nguyen Van Tho

Background: Coronavirus disease 2019 (COVID-19) may result in a severe acute respiratory syndrome that leads to a worldwide pandemic. Despite the increasing understanding of COVID-19 disease, the mortality rate of hospitalized COVID-19 patients remains high.

Objective: To investigate the risk factors related to the mortality of admitted COVID-19 patients during the peak of the epidemic from August 2021 to October 2021 in Vietnam.

Methods: This is a prospective cohort study performed at the Hospital for Rehabilitation-Professional diseases. The baseline and demographic data, medical history, clinical examination, the laboratory results were recorded for patients admitted to the hospital with confirmed COVID-19. A radiologist and a pulmonologist will read the chest radiographs on admission and calculate the Brixia scores to classify the severity of lung abnormalities. Patients were followed up until beingrecovered or their death. Comparison of clinical and subclinical characteristics between recovery and death groups to find out risk factors related to the death of COVID-19 patients.

Results: Among 104 admitted COVID-19 patients, men accounted for 42.3%, average age of 61.7 ± 13.7. The most common symptoms were fever 76.9%, breathlessness 74%, and fatigue 53.8%. The majority (84.6%) of the study population had at least one co-morbidity, including hypertension (53.8%), diabetes (25.9%), gastritis (19.2%), ischemic heart disease (15.4) %), stroke (9.6%) and osteoarthritis (9.6%). The rate of mild and moderate COVID-19 is 13.4%, severe 32.7%, and critical 40.4%. There are 88 inpatients (84.6%) who needed respiratory support. The median hospital stay was 13 days (IQR 10-17.75 days). The rate of intubated patients with mechanical ventilation was 31.7%. The overall mortality rate was 29.8%. Risk factors related to death included Brixia scores > 9, Urea > 7 mmol/L, Ferrtin > 578 ng/ml, Failure to get vaccinated, Age > 60 years, and Low Oxygen SpO2 < 87% (BUFFALO).

Conclusion: The main result of the study is the independent risk factors related to the death of admitted COVID-19 patients including Brixia scores > 9, Urea > 7 mmol/L, Ferrtin > 578 ng/ml, Failure to get vaccinated, Age > 60 years, and Low Oxygen SpO2 < 87% ((BUFFALO) which suggests that these COVID-19 patients should be closely followed up.

背景:2019冠状病毒病(新冠肺炎)可能导致严重急性呼吸综合征,从而导致全球大流行。尽管人们对新冠肺炎疾病的了解越来越多,但新冠肺炎住院患者的死亡率仍然很高。目的:调查2021年8月至2021年10月越南疫情高峰期新冠肺炎住院患者死亡率的相关危险因素。方法:这是一项在职业病康复医院进行的前瞻性队列研究。记录确诊为新冠肺炎的住院患者的基线和人口统计数据、病史、临床检查和实验室结果。放射科医生和肺科医生将在入院时阅读胸部X线片,并计算Brixia评分,以对肺部异常的严重程度进行分类。对患者进行随访,直至被覆盖或死亡。比较康复组和死亡组的临床和亚临床特征,以找出与新冠肺炎患者死亡相关的危险因素。结果:在104名新冠肺炎住院患者中,男性占42.3%,平均年龄为61.7±13.7岁。最常见的症状是发热76.9%,呼吸困难74%,疲劳53.8%。大多数(84.6%)研究人群至少有一种合并发病率,包括高血压(53.8%)、糖尿病(25.9%)、胃炎(19.2%)、缺血性心脏病(15.4%)、中风(9.6%)和骨关节炎(9.6%,危重40.4%。需要呼吸支持的住院患者有88人(84.6%)。中位住院时间为13天(IQR 10-17.75天)。机械通气插管患者的发病率为31.7%。总死亡率为29.8%。与死亡相关的危险因素包括Brixia评分>9,尿素>7mmol/L,Ferrtin>578ng/ml,未接种疫苗,年龄>60岁,结论:研究的主要结果是与新冠肺炎住院患者死亡相关的独立危险因素,包括Brixia评分>9,尿素>7mmol/L,Ferrtin>578ng/ml,未接种疫苗,年龄>60岁,低氧SpO2<87%(BUFFALO),这表明这些新冠肺炎患者应密切随访。
{"title":"Risk Factors Related to the Death of Admitted COVID-19 Patients: A Buffalo Study.","authors":"Doan Le Minh Hanh,&nbsp;Phan Thai Hao,&nbsp;Do Thi Tuong Oanh,&nbsp;Nguyen Van Tho","doi":"10.2174/18743064-v17-e230322-2022-21","DOIUrl":"https://doi.org/10.2174/18743064-v17-e230322-2022-21","url":null,"abstract":"<p><strong>Background: </strong>Coronavirus disease 2019 (COVID-19) may result in a severe acute respiratory syndrome that leads to a worldwide pandemic. Despite the increasing understanding of COVID-19 disease, the mortality rate of hospitalized COVID-19 patients remains high.</p><p><strong>Objective: </strong>To investigate the risk factors related to the mortality of admitted COVID-19 patients during the peak of the epidemic from August 2021 to October 2021 in Vietnam.</p><p><strong>Methods: </strong>This is a prospective cohort study performed at the Hospital for Rehabilitation-Professional diseases. The baseline and demographic data, medical history, clinical examination, the laboratory results were recorded for patients admitted to the hospital with confirmed COVID-19. A radiologist and a pulmonologist will read the chest radiographs on admission and calculate the Brixia scores to classify the severity of lung abnormalities. Patients were followed up until beingrecovered or their death. Comparison of clinical and subclinical characteristics between recovery and death groups to find out risk factors related to the death of COVID-19 patients.</p><p><strong>Results: </strong>Among 104 admitted COVID-19 patients, men accounted for 42.3%, average age of 61.7 ± 13.7. The most common symptoms were fever 76.9%, breathlessness 74%, and fatigue 53.8%. The majority (84.6%) of the study population had at least one co-morbidity, including hypertension (53.8%), diabetes (25.9%), gastritis (19.2%), ischemic heart disease (15.4) %), stroke (9.6%) and osteoarthritis (9.6%). The rate of mild and moderate COVID-19 is 13.4%, severe 32.7%, and critical 40.4%. There are 88 inpatients (84.6%) who needed respiratory support. The median hospital stay was 13 days (IQR 10-17.75 days). The rate of intubated patients with mechanical ventilation was 31.7%. The overall mortality rate was 29.8%. Risk factors related to death included Brixia scores > 9, Urea > 7 mmol/L, Ferrtin > 578 ng/ml, Failure to get vaccinated, Age > 60 years, and Low Oxygen SpO2 < 87% (BUFFALO).</p><p><strong>Conclusion: </strong>The main result of the study is the independent risk factors related to the death of admitted COVID-19 patients including Brixia scores > 9, Urea > 7 mmol/L, Ferrtin > 578 ng/ml, Failure to get vaccinated, Age > 60 years, and Low Oxygen SpO2 < 87% ((BUFFALO) which suggests that these COVID-19 patients should be closely followed up.</p>","PeriodicalId":39127,"journal":{"name":"Open Respiratory Medicine Journal","volume":"17 ","pages":"e187430642302200"},"PeriodicalIF":0.0,"publicationDate":"2023-04-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10351335/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"71427650","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Risk Factors Related to the Death of Admitted COVID-19 Patients: A Buffalo Study 与新冠肺炎住院患者死亡相关的危险因素:水牛城研究
Q3 Medicine Pub Date : 2023-04-03 DOI: 10.2174/18743064-v17-e230403-2022-21
Doan Le Minh Hanh, Phan Thai Hao, Do Thi Tuong Oanh, N. V. Tho
Coronavirus disease 2019 (COVID-19) may result in a severe acute respiratory syndrome that leads to a worldwide pandemic. Despite the increasing understanding of COVID-19 disease, the mortality rate of hospitalized COVID-19 patients remains high. To investigate the risk factors related to the mortality of admitted COVID-19 patients during the peak of the epidemic from August 2021 to October 2021 in Vietnam. This is a prospective cohort study performed at the Hospital for Rehabilitation–Professional diseases. The baseline and demographic data, medical history, clinical examination, the laboratory results were recorded for patients admitted to the hospital with confirmed COVID-19. A radiologist and a pulmonologist will read the chest radiographs on admission and calculate the Brixia scores to classify the severity of lung abnormalities. Patients were followed up until beingrecovered or their death. Comparison of clinical and subclinical characteristics between recovery and death groups to find out risk factors related to the death of COVID-19 patients Among 104 admitted COVID-19 patients, men accounted for 42.3%, average age of 61.7 ± 13.7. The most common symptoms were fever 76.9%, breathlessness 74%, and fatigue 53.8%. The majority (84.6%) of the study population had at least one co-morbidity, including hypertension (53.8%), diabetes (25.9%), gastritis (19.2%), ischemic heart disease (15.4) %), stroke (9.6%) and osteoarthritis (9.6%). The rate of mild and moderate COVID-19 is 13.4%, severe 32.7%, and critical 40.4%. There are 88 inpatients (84.6%) who needed respiratory support. The median hospital stay was 13 days (IQR 10-17.75 days). The rate of intubated patients with mechanical ventilation was 31.7%. The overall mortality rate was 29.8%. Risk factors related to death included Brixia scores > 9, Urea > 7 mmol/L, Ferrtin > 578 ng/ml, Failure to get vaccinated, Age > 60 years, and Low Oxygen SpO2 < 87% (BUFFALO). The main result of the study is the independent risk factors related to the death of admitted COVID-19 patients including Brixia scores > 9, Urea > 7 mmol/L, Ferrtin > 578 ng/ml, Failure to get vaccinated, Age > 60 years, and Low Oxygen SpO2 < 87% ((BUFFALO) which suggests that these COVID-19 patients should be closely followed up.
2019冠状病毒病(新冠肺炎)可能导致严重急性呼吸综合征,从而导致全球大流行。尽管人们对新冠肺炎疾病的了解越来越多,但新冠肺炎住院患者的死亡率仍然很高。调查2021年8月至2021年10月越南疫情高峰期新冠肺炎住院患者死亡率的相关风险因素。这是一项在专业疾病康复医院进行的前瞻性队列研究。记录确诊为新冠肺炎的住院患者的基线和人口统计数据、病史、临床检查和实验室结果。放射科医生和肺科医生将在入院时阅读胸部X线片,并计算Brixia评分,以对肺部异常的严重程度进行分类。对患者进行随访,直至被覆盖或死亡。比较康复组和死亡组的临床和亚临床特征,找出与新冠肺炎患者死亡相关的危险因素在104名入院的新冠肺炎患者中,男性占42.3%,平均年龄为61.7±13.7。最常见的症状是发热76.9%,呼吸困难74%,疲劳53.8%。大多数(84.6%)研究人群至少有一种合并发病率,包括高血压(53.8%)、糖尿病(25.9%)、胃炎(19.2%)、缺血性心脏病(15.4%)、中风(9.6%)和骨关节炎(9.6%,危重40.4%。需要呼吸支持的住院患者有88人(84.6%)。中位住院时间为13天(IQR 10-17.75天)。机械通气插管患者的死亡率为31.7%。总死亡率为29.8%。与死亡相关的危险因素包括Brixia评分>9,尿素>7mmol/L,Ferrtin>578ng/ml,未接种疫苗,年龄>60岁,低氧SpO2<87%(BUFFALO)。该研究的主要结果是与入院新冠肺炎患者死亡相关的独立风险因素,包括Brixia评分>9,尿素>7 mmol/L,Ferrtin>578 ng/ml,未能接种疫苗,年龄>60岁,低氧SpO2<87%(BUFFALO),这表明应密切跟踪这些新冠肺炎患者。
{"title":"Risk Factors Related to the Death of Admitted COVID-19 Patients: A Buffalo Study","authors":"Doan Le Minh Hanh, Phan Thai Hao, Do Thi Tuong Oanh, N. V. Tho","doi":"10.2174/18743064-v17-e230403-2022-21","DOIUrl":"https://doi.org/10.2174/18743064-v17-e230403-2022-21","url":null,"abstract":"\u0000 \u0000 Coronavirus disease 2019 (COVID-19) may result in a severe acute respiratory syndrome that leads to a worldwide pandemic. Despite the increasing understanding of COVID-19 disease, the mortality rate of hospitalized COVID-19 patients remains high.\u0000 \u0000 \u0000 \u0000 To investigate the risk factors related to the mortality of admitted COVID-19 patients during the peak of the epidemic from August 2021 to October 2021 in Vietnam.\u0000 \u0000 \u0000 \u0000 This is a prospective cohort study performed at the Hospital for Rehabilitation–Professional diseases. The baseline and demographic data, medical history, clinical examination, the laboratory results were recorded for patients admitted to the hospital with confirmed COVID-19. A radiologist and a pulmonologist will read the chest radiographs on admission and calculate the Brixia scores to classify the severity of lung abnormalities. Patients were followed up until beingrecovered or their death. Comparison of clinical and subclinical characteristics between recovery and death groups to find out risk factors related to the death of COVID-19 patients\u0000 \u0000 \u0000 \u0000 Among 104 admitted COVID-19 patients, men accounted for 42.3%, average age of 61.7 ± 13.7. The most common symptoms were fever 76.9%, breathlessness 74%, and fatigue 53.8%. The majority (84.6%) of the study population had at least one co-morbidity, including hypertension (53.8%), diabetes (25.9%), gastritis (19.2%), ischemic heart disease (15.4) %), stroke (9.6%) and osteoarthritis (9.6%). The rate of mild and moderate COVID-19 is 13.4%, severe 32.7%, and critical 40.4%. There are 88 inpatients (84.6%) who needed respiratory support. The median hospital stay was 13 days (IQR 10-17.75 days). The rate of intubated patients with mechanical ventilation was 31.7%. The overall mortality rate was 29.8%. Risk factors related to death included Brixia scores > 9, Urea > 7 mmol/L, Ferrtin > 578 ng/ml, Failure to get vaccinated, Age > 60 years, and Low Oxygen SpO2 < 87% (BUFFALO).\u0000 \u0000 \u0000 \u0000 The main result of the study is the independent risk factors related to the death of admitted COVID-19 patients including Brixia scores > 9, Urea > 7 mmol/L, Ferrtin > 578 ng/ml, Failure to get vaccinated, Age > 60 years, and Low Oxygen SpO2 < 87% ((BUFFALO) which suggests that these COVID-19 patients should be closely followed up.\u0000","PeriodicalId":39127,"journal":{"name":"Open Respiratory Medicine Journal","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-04-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"46959661","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
期刊
Open Respiratory Medicine Journal
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1